Hostname: page-component-76fb5796d-x4r87 Total loading time: 0 Render date: 2024-04-26T08:08:08.243Z Has data issue: false hasContentIssue false
  • English
  • Français

The prevalence of neuroleptic malignant syndrome in learning disability

Published online by Cambridge University Press:  13 June 2014

Caryl N Morgan  and
Renarta Rowe
Caryl N Morgan
Affiliation:
Janet Shaw Clinic, Brooklands, Marston Green, Birmingham, B37 7HL, England
Renarta Rowe
Affiliation:
West Midlands Forensic Rotation, England
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: No information has been published on the incidence of neuroleptic malignant syndrome in learning disability. However, some studies of individuals who have developed neuroleptic malignant syndrome have suggested that individuals with learning disabilities may be over represented. This study aims to identify the association between learning disability and neuroleptic malignant syndrome.

Method: A retrospective case-note analysis was performed with psychiatric case notes for clients with learning disability, in two geographical catchment areas. It was recorded whether clients had been exposed to neuroleptics, and whether any neurological symptoms had subsequently developed which could have been suggestive of neuroleptic malignant syndrome.

Results: It was found that 301 individuals had been exposed to neuroleptics, out of 570 case notes examined. Only one case of neuroleptic malignant syndrome was identified, giving a lifetime prevalence rate of 0.3%.

Conclusion: This study failed to demonstrate a higher than expected prevalence of neuroleptic malignant syndrome in clients with learning disability exposed to neuroleptics.

Keywords

Learning disabilityNeuroleptic malignant syndromeOutpatient
Type
Case reports
Information
Irish Journal of Psychological Medicine , Volume 20 , Issue 3 , September 2003 , pp. 102 - 104
Copyright
Copyright © Cambridge University Press 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Jahan, MS, Farooque, AI, Wahid, Z. Neuroleptic malignant syndrome. JAMA. 1992; 84(11): 966–970.Google ScholarPubMed
2.Kohen, D, Bristow, M. Neuroleptic malignant syndrome. Advances in Psychiatric Treatment. 1996; 2: 151–157CrossRefGoogle Scholar
3.Fitzgerald, B, Middleton, JK, Cooper, SA. Adverse effects of summer amongst people with learning disability: A case report. J Intellect Disabil. 1997; 42(3): 273–277.CrossRefGoogle Scholar
4.Addonizio, G, Susman, VL, Roth, SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiat 1987; 22: 1004–1020.CrossRefGoogle ScholarPubMed
5.Pearlman, CA. Neuroleptic malignant syndrome. A review of the literature. J Clin Psychopharm. 1986; 6: 257–273.CrossRefGoogle ScholarPubMed
6.Clarke, DJ, Kelly, S, Thinn, K, Corbett, JA. Psychotropic drugs and mental retardation. 1. Disabilities and the prescription of drugs for behaviour and for epilepsy in three residential settings. J Ment Def Res. 1990 Oct; 34 (5): 385–395.Google ScholarPubMed
7.Robertson, J, Emerson, E, Gregory, N, Hatton, C, Kessissoglou, S, Hallam, A. Receipt of psychotropic medication by people with intellectual disability in residential settings. B J Intellect Dis. 2000 Oct; 44 (6): 666–676.CrossRefGoogle ScholarPubMed
8.Levenson, JL. Neuroleptic malignant syndrome. Am J of psychiatry. 1985; 142: 1137–1145.Google ScholarPubMed
9.Rosebush, P. Stewart, T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry. 1989; 146: 717–725.Google ScholarPubMed
10.Adityanjee, , Aderibigbe, YA, Matthews, T. Epidemiology of neuroleptic malignant syndrome. Clin Neuropharmacol 1999; 22(3): 151–158.Google ScholarPubMed
11.DSM IV. American Psychiatric Association. 1994.Google Scholar